HomeProtein ExpressionSerotonin Synthesis and Metabolism

Serotonin Synthesis and Metabolism

Serotonin (5-hydroxytryptamine) is principally found stored in three main cell types - i) serotonergic neurons in the CNS and in the intestinal myenteric plexus, ii) enterochromaffin cells in the mucosa of the gastrointestinal tract, and iii) in blood platelets. Serotonergic neurons and enterochromaffin cells can synthesize serotonin from its precursor amino acid L-tryptophan, whereas platelets rely upon uptake of serotonin for their stores. Likewise, serotonergic neurons also have the capacity for amine uptake via serotonin transporters. Serotonin is also synthesized in the pineal gland as a precursor for the subsequent enzymatic formation of the pineal hormone melatonin (N-acetyl-5-methoxytryptamine).

The biochemical pathway for serotonin synthesis initially involves the conversion of L-tryptophan to 5-hydroxytryptophan by the enzyme L-tryptophan hydroxylase (TPH), which has been found both in cytosolic and particulate brain cell fractions. This enzyme provides the rate-limiting step for serotonin synthesis, in the same manner that norepinephrine and dopamine synthesis in adrenergic and dopaminergic neurons is controlled by the ability of the related enzyme, L-tyrosine hydroxylase, to convert L-tyrosine to L-dihydroxyphenylalanine (L-DOPA). Some inhibitors of TPH (e.g. α-propyldopacetamide) are also active against tyrosine hydroxylase, whereas others such as p-chlorophenylalanine are more selective for TPH. Although p-chloroamphetamine and fenfluramine can also inhibit TPH, they have important actions (including neurotoxic effects) upon various other regulatory processes of serotonergic neuronal function. The identification of two enzyme isoforms, called TPH1 and TPH2, which are apparently associated selectively with peripheral tissues and the brain, respectively, suggests the possibility that drug inhibitors with specificity for targeting individual isoforms may be found in the future.

The subsequent metabolic step in the synthesis of serotonin (and also norepinephrine or dopamine) involves the decarboxylation of 5-hydroxytryptophan (and L-DOPA) by the action of the cytosolic enzyme L-aromatic amino acid decarboxylase. Inhibitors of this enzyme include the drugs benserazide and carbidopa, which do not cross the blood brain barrier, and are used clinically to prevent peripheral decarboxylation of the L-DOPA administered as a precursor for central dopamine formation in Parkinsonian patients.

Metabolism of serotonin is carried out primarily by the outer mitochondrial membrane enzyme monoamine oxidase (MAO), which occurs as two molecular subtypes called MAO-A and MAO-B. Both subtypes have a widespread occurrence in the brain and in peripheral tissues, although they do show some differences, including species-related variations, with respect to the extent of their presence in certain tissues and cell types. In addition, the subtypes show differences in their substrate specificities and their sensitivities to certain inhibitors. For example, MAO-A is more selective for serotonin oxidation by being able to metabolize serotonin with a much lower Km value (and higher affinity for the substrate) than MAO-B. Inhibition of MAO-A activity to prevent serotonin metabolism in the CNS has been linked to the antidepressant properties of a number of subtype selective (e.g. moclobemide) and nonselective (e.g. phenelzine) MAO inhibitors in clinical use. Interestingly, however, immunohistochemical studies have suggested that serotonin-containing neurons may themselves contain only MAO-B. Reports defining the crystal structure of both MAO-A and B have provided important insights into molecular topographical features of each subtype that may control drug access to their catalytic sites, thus contributing to their different substrate and inhibitor specificities. The action of MAO converts serotonin to 5-hydroxyindole acetaldehyde, which in turn is readily metabolized, principally by an isoform of aldehyde dehydrogenase (ALDH2) located in mitochondria, to produce 5-hydroxyindole acetic acid as the major excreted metabolite of serotonin. An alternative metabolic route via aldehyde reductase can convert 5-hydroxyindole acetaldehyde to 5-hydroxytryptophol, but this pathway is normally considered to be insignificant.


Ro 41-1049: N-(2-Aminoethyl)-5-(3-fluorophenyl)-4-thiazolecarboxamide

Beck O, Helander A, Carlsson S, Borg S. 1995. Changes in Serotonin Metabolism during Treatment with the Aldehyde Dehydrogenase Inhibitors Disulfiram and Cyanamide. 77(5):323-326.
Binda C, Hubálek F, Li M, Edmondson DE, Mattevi A. 2004. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. 564(3):225-228.
Caraci F, Crupi R, Drago F, Spina E. 2011. Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. CDM. 12(6):570-577.
Cesura AM, Pletscher A. 1992. The new generation of monoamine oxidase inhibitors.171-297.
Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B. 1998. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. Journal of Affective Disorders. 51(3):287-303.
Feldman R, Meyer J, Quenzer L. 1977. Principles od Neuropsychopharmacology. Massachusetts. Sinauer Associates.
keszthelyi d, troost fj, masclee aam. 2009. Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. 21(12):1239-1249.
Keung WM, Vallee BL. 1998. Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. Proceedings of the National Academy of Sciences. 95(5):2198-2203.
Lesch K, Araragi N, Waider J, van den Hove D, Gutknecht L. 2012. Targeting brain serotonin synthesis: insights into neurodevelopmental disorders with long-term outcomes related to negative emotionality, aggression and antisocial behaviour. Phil. Trans. R. Soc. B. 367(1601):2426-2443.
Lindros KO, Badger T, Ronis M, Ingelman-Sundberg M, Koivusalo M. 1995. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor. J Pharmacol Exp Ther. 275(1):79-83.
Ma J, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T. 2004. Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors. Journal of Molecular Biology. 338(1):103-114.
Shih JC, Chen K, Ridd MJ. 1999. MONOAMINE OXIDASE: From Genes to Behavior. Annu. Rev. Neurosci.. 22(1):197-217.
Stokes AH, Xu Y, Daunais JA, Tamir H, Gershon MD, Butkerait P, Kayser B, Altman J, Beck W, Vrana KE. p-Ethynylphenylalanine. 74(5):2067-2073.
Visser AKD, van Waarde A, Willemsen ATM, Bosker FJ, Luiten PGM, den Boer JA, Kema IP, Dierckx RAJO. 2011. Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications. Eur J Nucl Med Mol Imaging. 38(3):576-591.
Walther DJ, Bader M. 2003. A unique central tryptophan hydroxylase isoform. Biochemical Pharmacology. 66(9):1673-1680.
Youdim M. 2004. Therapeutic Applications of Selective and Non-Selective Inhibitors of Monoamine Oxidase A and B that do not Cause Significant Tyramine Potentiation. NeuroToxicology. 25(1-2):243-250.